Navigation Links
Families of SMA Releases Newsletter Describing the Scientific Strategy Behind Antisense Drugs for Spinal Muscular Atrophy

Elk Grove Village, IL (PRWEB) December 09, 2013

Families of SMA has released a new edition of the Compass Newsletter, a publication dedicated to research updates. This newsletter was produced in a collaboration between Families of SMA, Biogen Idec, and Isis Pharmaceuticals. It describes the scientific strategy behind Antisense Drugs. It also provides updates on the ongoing research and clinical trials for this class of SMA drugs.

This edition of Compass, includes information about:

-The ABC's of Antisense Drugs

-ISIS-SMNRX Program Update on Ongoing and Future Clinical Trials

-FSMA Grant Award to Dr. Adrian Krainer at CSHL to Assess Influence of Backbone Chemistry on Antisense Drugs

-FSMA Grant Award to Drs. Arthur Burghes and Christian Lorson for Novel Antisense Therapies

-Report on New Data from the Completed Phase I Study Evaluating the Safety of Isis-SMNRX

Antisense drugs are small snippets of synthetic genetic material that bind to RNA (short for ribonucleic acid). The main factor driving where the antisense drug binds to the RNA is the nucleic acid sequence used. Nucleic acids consist of a chain of linked units called nucleotides. Antisense drugs are typically 12-21 nucleotides that are chemically modified to bring about the appropriate drug response.

How does the antisense approach work for SMA?
SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene. The SMN1 gene produces most of the SMN protein, which is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle function. The severity of SMA is correlated with the amount of SMN protein in the cell. A second closely related back-up gene called SMN2 exists that normally produces a truncated, low-functioning form of SMN protein. Antisense therapy could be used to change the functioning of the SMN2 gene by utilizing alternative RNA splicing. Alternative splicing is a normal mechanism that the cell uses to produce different, but closely related proteins from a single gene.

About Families of SMA
Families of SMA has awarded four new drug discovery projects since the start of 2013. The research progress provides hope that one day we will live in a world without SMA. There are now 15 new SMA drug programs in development, including 4 in clinical trials. This pipeline has expanded from just 4 programs 5 years ago. Families of SMA has funded over half of all the ongoing drug programs for SMA. The FSMA research approach funds programs at early stages, and then partners with companies to take them through clinical trials. Supporting multiple programs gives different approaches for a SMA therapy, which increases the chances of success and accelerates the timeline to a treatment and cure.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Super-Sod is Donating their Doc's Raised Garden Kits to Families and Community Gardens
2. Families Grateful for At-work Access to Youth Cardiac, Concussion Screenings
3. Narconon International Publishes Indispensible Guide for Families Dealing with Addiction
4. IBT’s Top Ten Holiday Tips Minimize Challenges for Children with Autism and Their Families
5. A New Website for Families to Turn: New Health and Wellness Promotion Website Launched by Family Voices
6. YMCA Thanksgiving Dinner Supports Families in Need
7. 1-800-HOMECARE Comments on Recent Nursing Home Theft That Strikes Seniors andFamilies
8. STAR Center Raising Funds for Special Needs Children of Military Families
9. Princeton study: Military children and their families remain an invisible subculture
10. Researchers at Pace University Explore the Lived Experiences of Families Members That Have the Possible Risk of Genetic Mutations That Cause Sudden Cardiac Death
11. Families, Businesses & Special Needs Children Rally to Support America's Special Kidz (A.S.K.)'s First Fundraiser
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: